FT US Healthcare and Life Sciences Conference
 
Scott Bruder, MD, PhD
Chief Medical and Scientific Officer
Stryker
Scott Bruder is the Chief Medical and Scientific Officer of Stryker Corporation, where he oversees the clinical and scientific efforts across the company, including academic, industrial and governmental scientific partnerships. The role also leads company-wide efforts related to the innovation, evidence generation and intellectual property strategies.  Dr Bruder has a long and proven track record of performance across multiple roles in his career, and is an accomplished researcher and innovator with more than 20 issued and pending US and international patents.  He has published nearly 150 original articles, book chapters and abstracts in peer-reviewed journals, and received numerous awards from the American Academy of Orthopaedic Surgeons, the Orthopaedic Research Society and the Association of Bone and Joint Surgeons.  Previously, Dr Bruder was employed at Becton, Dickinson and Company as the Chief Science and Technology Officer, where he was responsible for identifying and cultivating new growth opportunities, improving the product development system and enhancing global research capabilities.  Prior to that, he spent eight years at Johnson & Johnson in a variety of senior executive and scientific roles.  Earlier in his career, he held various leadership roles in basic, applied and clinical research at Anika Therapeutics, and Osiris Therapeutics.  Mr Bruder is a magna cum laude graduate from Brown University, and CWRU School of Medicine, where he simultaneously earned a PhD degree in Stem Cell Biology.  He obtained further clinical training at Albert Einstein Medical Center and the University of Pennsylvania before joining the industrial sector.
 
John Capek PhD
Executive Vice President, Medical Devices
Abbott
 John Capek, PhD is Executive Vice President, Medical Devices of Abbott. Dr Capek was appointed to his current position in July 2007 and is responsible for Abbott's Vascular, Diabetes Care, Vision Care and Animal Health businesses. Previously, he served as Senior Vice President, Vascular, heading up Abbott's global vascular business.

Before joining Abbott, Dr Capek served in various management roles at Guidant Corporation, including President, Guidant Vascular Intervention and Vice President and General Manager of Bioabsorbable Vascular Solutions. He also served as Vice President and General Manager of Guidant Germany and Vice President, Marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr Capek was Manager of New Product Technology at Eli Lilly & Company.

He has a Bachelor's degree in Biomedical Engineering, a Master's degree in Biomedical Engineering, a Master's degree in Electrical Engineering, a PhD in Biomedical Engineering, and a Master's degree in Business Administration from Rensselaer Polytechnic Institute.
 
Jeff George
Global Head, Sandoz and Executive Committee Member
Sandoz

Jeff George has led Sandoz since October 2008. Sandoz is the world’s second-largest generic pharmaceutical company globally with 2011 sales of USD 9.5 billion. Sandoz employs over 24,000 people in more than 130 countries, and its product price points are accessible to nearly 90% of the world’s population. Sandoz is a global leader in differentiated generics such as injectables and is the pioneer and #1 global player in the emerging field of biosimilars, or “follow on biologics”.

Prior to assuming his current position, Mr George was Head of Emerging Markets for the Middle East, Africa, Southeast Asia and the CIS countries for Novartis Pharma, where he led a team of over 3,000 people across more than 65 markets. He joined Novartis in January 2007 as Head of Western & Eastern Europe for Novartis Vaccines, where he was responsible for 25 markets from the UK to Russia.

Before joining Novartis, Mr George was Senior Director of Strategic Planning and Business Development at Gap Inc. Prior to this, he was an Engagement Manager at McKinsey & Company and has also worked in emerging markets private equity in South Africa and the US.

Mr George holds an MBA from Harvard University and a Masters from Johns Hopkins University’s School of Advanced International Studies (SAIS). He also holds a BA in international relations from Carleton College.

 
Jan Groen PhD
Chief Executive Officer
MDxHealth

Dr Jan Groen joined MDxHealth in 2010 and has more than 25 years of experience in the clinical diagnostic industry, with a particular focus on emerging technologies, product development and commercialization. Dr Groen was previously the President and Chief Operating Officer of Agendia where he was responsible for their United States and European diagnostic operations. Prior to this, he served as Vice-President of Research & Development at Focus Diagnostics, a subsidiary of Quest Diagnostics, in California. Dr Groen has held numerous management and scientific positions at ViroClinics, the Erasmus Medical Center, and Akzo-Nobel. He is a supervisory board member of IBL International. Dr Groen holds a PhD from the Erasmus University Rotterdam and has published more than 125 papers in international scientific journals in the field of clinical diagnostics.

 
Fred Hassan
Managing Director, Healthcare
Warburg Pincus

Fred Hassan is a Partner and Managing Director with the private equity firm Warburg Pincus. He is also Chairman of Bausch & Lomb and of Avon, as well as a Board member of Time Warner.

Mr Hassan is the former Chairman of the Board and Chief Executive Officer of Schering-Plough Corporation. Prior to joining Schering-Plough in April 2003, he was Chairman and Chief Executive Officer of Pharmacia Corporation – a company that was formed in March 2000 as a result of the merger of Monsanto and Pharmacia and Upjohn. Mr Hassan joined Pharmacia & Upjohn as Chief Executive Officer in 1997. Prior to this, Mr Hassan was Executive Vice President of Wyeth, formerly known as American Home Products, with responsibility for its pharmaceutical and medical products business. He was elected to Wyeth’s Board of Directors in 1995. Earlier in his career, Mr Hassan spent 17 years with Sandoz Pharmaceuticals (now Novartis) and headed its US pharmaceuticals business.

Mr Hassan has chaired three significant pharmaceutical industry organizations - The Pharmaceutical Research and Manufacturers of America (PhRMA), The International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and the HealthCare Institute of New Jersey (HINJ). Mr Hassan is also a member of The Business Council. His book, Reinvent, A Leader’s Playbook for Serial Success was published in February 2013 by Wiley.

Mr Hassan received a BS degree in Chemical Engineering from the Imperial 
College of Science and Technology at the University of London and an MBA from Harvard Business School.
 
Arthur Higgins
Senior Consultant
Blackstone Healthcare Partners

Arthur Higgins is employed as Senior Consultant with Blackstone Healthcare Partners of The Blackstone Group. He previously served as Chairman of the Board of Management of Bayer HealthCare, a developer and manufacturer of human and animal health products.

Prior to joining Bayer HealthCare in 2004, Mr Higgins served as Chairman, President and Chief Executive Officer of Enzon Pharmaceuticals, from 2001 to 2004. Prior to joining Enzon Pharmaceuticals, Mr Higgins spent 14 years with Abbott Laboratories, most recently as President of the Pharmaceutical Products Division from 1998 to 2001. He is a past member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), of the Council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is a member of the Board of Directors of Zimmer, Resverlogix Corp, Ecolab, and Catalent Pharma.

Mr Higgins graduated from Strathclyde University, Scotland and holds a B.S. in Biochemistry.

 
Colin Hill
CEO and Co-Founder
GNS Healthcare

Colin Hill is a frequent speaker at international scientific and industry conferences. He has appeared in numerous publications and television segments including The Wall Street Journal, CNBC Morning Call, Nature, Forbes, Wired, and The Economist, and is the author of the “Healthcare 2020” blog on Forbes.com. He serves as Chairman of GNS Healthcare’s parent company Via Science, a leading big data analytics company focused on business intelligence, finance, and economic forecasting. He also serves on the board of directors of AesRx, a biopharmaceutical company dedicated to the development of a new treatment for sickle cell disease, on the advisory board of the Boston Medical Center’s philanthropic trust, and as the chair of the industrial advisory board of EBICS.

In 2004, Mr Hill was named to MIT Technology Review’s TR35 list of the top innovators in the world under the age of 35. He graduated from Virginia Tech with a degree in physics and earned master’s degrees in physics from McGill University and Cornell University.
 
Terry Hisey
Vice Chairman, US Life Sciences Leader
Deloitte

R.T. (Terry) Hisey is the Vice Chairman and US Life Sciences Leader for Deloitte LLP. In this role, he leads the firm’s service efforts in the areas of audit, tax, strategy, performance improvement and technology consulting to assist clients in achieving sustainable competitive advantage through strategic change. His Life Sciences experience spans the entire value chain including drug discovery & development, commercial operations, production & distribution, and regulatory
compliance. As Chairman of the Life Sciences Advisory Board for Deloitte Research and Steering Committee member for the Deloitte Center for Health Solutions, Mr Hisey guides thought leadership and advises clients on transformative opportunities in the industry including comparative effectiveness, informatics, social media and globalization. In addition to his client work, Mr Hisey is a noted industry authority, frequent speaker, a Strategy Advisor to Pharmaceutical Executive Magazine, and guest lecturer at several schools including the University of Pennsylvania, and the University of California at Berkeley. He is also a member of several industry associations and advisory boards.
 
Paul Hudson
Executive Vice President, North America
AstraZeneca

Paul Hudson is responsible for leading AstraZeneca’s commercial operations in North America and represents the region as a member of the Senior Executive Team. In this capacity he is accountable for driving growth and maximizing contribution of North America to AstraZeneca’s global business.

Prior to his role in North America, Mr Hudson served as Representative Director and 
President of AstraZeneca K. K., the Japanese subsidiary of AstraZeneca PLC. He has served as a Standing Board Member of JPMA (Japan Pharmaceuticals Manufacturers Association) and EFPIA (European Federation of Pharmaceutical Industries and
Associations) in Japan. Previously he was President of AstraZeneca’s business in Spain. He joined AstraZeneca in 2006 as Vice President and Primary Care Director, UK.

Before AstraZeneca, Mr Hudson worked for Schering Plough, where he held roles of 
increasing seniority, including leading biologics global marketing, based in the US. He began his career at GSK UK and Sanofi-Synthelabo UK with roles in sales and marketing.

Mr Hudson received a degree in Economics from Manchester Metropolitan University 
and a DipM from the UK's Chartered Institute of Marketing. 
 
Andrew Jack
Pharmaceuticals Correspondent
Financial Times

Andrew Jack is the Pharmaceuticals Correspondent at the Financial Times. Prior to this he has held a series of posts including Accounting and Tax Correspondent, Paris Correspondent, and Moscow Bureau Chief.

Mr Jack joined the Financial Times in 1990. He was one of a group of journalists to be awarded the 1993 British Press Awards Reporting Team of the Year accolade for coverage of the Robert Maxwell affair.

He started his career as a public policy consultant and subsequently spent a year at the mayor’s office in New York as an Economic Development Officer. 

He graduated from Cambridge University with an honours degree in geography and was the Joseph Hodges Choate Memorial Fellow at Harvard University in 1988-89.  

The latest edition of his book, Inside Putin’s Russia, was published in paperback in the US at the end of 2005. He is the author of The French Exception, and previously wrote the specialist reports Insurance in France, Networking and Life at the Top. 

Mr Jack regularly appears on TV and radio.

 
Jan Lundberg PhD
Executive Vice President, Science and Technology and President
Lilly Research Laboratories

Jan Lundberg is Executive Vice President for Science and Technology and President of Lilly Research Laboratories. He is also a member of the company’s executive committee.

Dr Lundberg joined Eli Lilly and Company January 2010, with responsibility for Research and the Development Center of Excellence. Prior to assuming his position at Lilly, Dr Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of their senior executive team.  

After receiving his medical education and PhD, Dr Lundberg served as Professor at the Department of Pharmacology, Karolinska Institute, Stockholm, Sweden.  He has authored more than 500 publications of original articles in international peer-reviewed journals and is listed as one of the highly cited authors by the Institute for Scientific Information. His work has focused on cell signaling in integrated systems using multiple mediators (peptides, purines, and nitric oxide) with translational applications to nervous system, endocrine, inflammation and cardiovascular areas. This research has been highly recognized and has received several awards. He has also been appointed as Honorary Doctor at the Pharmaceutical Faculty, Uppsala University (2006).

Dr Lundberg serves on PhRMA’s Science and Regulatory Committee and is on the boards of the Biotechnology Industry Organization (BIO) and BioCrossroads.

 
David Meeker MD
President and Chief Executive Officer
Genzyme

David Meeker was appointed President and Chief Executive Officer of Genzyme in October 2011. Genzyme is a global biotechnology company committed to discovering and delivering transformative therapies for patients with rare and
special unmet medical needs. Dr Meeker oversees and provides the vision for the company’s two business units – Rare Diseases and Multiple Sclerosis - as well as its long-standing relationships with patient communities and dedicated workforce
of 10,000 employees.

In his career with Genzyme, he has held key positions of increasing responsibility, most recently as Chief Operating Officer. In this role, he was responsible for Genzyme’s commercial organization, overseeing its business units, country management organization, and global market access functions.As Chief Operating Officer, he played an important role in the integration with Sanofi.

Dr Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as Vice President, Medical Affairs, he was responsible for the development of therapeutic products, including
treatments in the current rare disease portfolio.

Prior to joining Genzyme, Dr Meeker was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He has authored more than 40 articles and multiple book
chapters.

Dr Meeker received his MD from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.
 
Reynold (Pete) Mooney
Global Leader, Life Sciences and Health Care
Deloitte Touche Tohmatsu

Reynold W. (Pete) Mooney is the Global Leader for Life Sciences and Health Care Industry Practice of Deloitte Touche Tohmatsu Limited. During his thirty year career he has served many of the Deloitte's largest life science clients and he has held numerous leadership roles within the Americas and Europe.  Mr Mooney began his career as a corporate strategy professional, working with his clients on issues of value and growth in industries undergoing transformation and globalization.  He became heavily involved in life sciences though his work in the early 90s with European chemicals manufacturers, primarily Bayer, DSM, ICI and Hoechst.  All four of these companies are case studies in transformation, the latter two being part of the genesis of today's AstraZeneca and Sanofi.

More recently, Mr Mooney has become involved in health care reform around the world and the implications this has for life sciences companies, particularly in the areas of market access and pricing.  He also works extensively in the area of research & development transformation, particularly as this area of the business radically restructures.  Mr Mooney is involved in several NGOs involved in charitable works around the world and has recently been assisting the Nelson Mandela Children's Hospital Trust with its pediatric facility in Johannesburg.

Mr Mooney holds dual UK and US citizenship.  He currently resides in the US.
 
John Noseworthy MD
President and CEO
Mayo Clinic

Dr John Noseworthy is President and Chief Executive Officer of Mayo Clinic, a not-for-profit organization operating in six states that is dedicated to medical care, research and education. Every year, more than a million people from all 50 states and nearly 150 countries come to Mayo Clinic for care.

Prior to his current appointment, Dr Noseworthy served as Chair of Mayo Clinic’s Department of Neurology, Medical Director of the Department of Development, and Vice Chair of the Mayo Clinic Rochester Executive Board.

During his tenure as CEO, Dr Noseworthy and his leadership team have created a strategic plan designed to ensure that Mayo Clinic remains a trusted resource for patients amid a rapidly changing health care environment – extending Mayo’s mission to new populations, providing care through more efficient delivery models, and increasing the personalization and immediacy of health care for all people. Examples of new initiatives include a proton beam cancer therapy program with two treatment centers – one in Phoenix and one in Rochester, Minnesota. – and development of a Mayo Clinic-affiliate network of high-quality medical practices throughout the country.

Dr Noseworthy is a Professor in the Department of Neurology, and continues to consult with patients. He specializes in multiple sclerosis and has spent more than two decades designing and conducting controlled clinical trials with generous support from the Medical Research Council of Canada, the Multiple Sclerosis Society of Canada, the National Multiple Sclerosis Society (USA) and the National Institutes of Health. Dr Noseworthy also is the author of more than 150 research papers, chapters, editorials and several books, including the three-volume textbook Neurological Therapeutics: Principles and Practice, now in its second edition. He also served as Editor-in-chief for Neurology, the official journal of the American Academy of Neurology.

Born in Melrose, Massachusetts, Dr Noseworthy received the MD degree from Dalhousie University in Halifax, Nova Scotia, Canada. He completed his neurology training at Dalhousie University and the University of Western Ontario, and a research fellowship at Harvard Medical School. He joined Mayo Clinic in 1990. He has received the Alumnus of the Year award from Dalhousie University (2005) and an Honorary Director of Science degree from the University of Western Ontario (2012). He is a Health Governor of the World Economic Forum.

 
Tom Pike
Chief Executive Officer
Quintiles

Tom Pike is the Chief Executive Officer of Quintiles, the leading provider of biopharmaceutical

business services with over $3B of revenues, and serves on its Board of Directors. Quintiles

services include clinical, commercial, technology, consulting and other services for the

healthcare sector. A global company based in North Carolina, Quintiles just celebrated its 30

year anniversary.


Prior to Quintiles, Mr Pike spent 22 years at Accenture, including 13 years in global

leadership roles, partnering with many top companies around the world. He has worked

across many industry sectors, concentrating much of his career on the technology and

healthcare sector. He also spent several years with McKinsey and Company, and helped

launch a healthcare company with a private equity firm.

 

 
Ian Read
Chairman of the Board and Chief Executive Officer
Pfizer

Ian Read is Chairman of the Board and Chief Executive Officer of Pfizer, one of the world's premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines and vaccines along with many of the world's best-known consumer healthcare products. Previously, he served as Senior Vice President, Pfizer, and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units - Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.

Mr Read began his career with Pfizer in 1978 as an Operational Auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer's largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, he was appointed President of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Mr Read later became accountable for operations in both the Africa/Middle East region and Latin America as well.

Mr Read serves on the Boards of PhRMA, Kimberly-Clark and the Partnership for New York City.

Mr Read received his BSc in Chemical Engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978.
 
Amy Schulman
Executive Vice President and General Counsel; Business Unit Lead, Consumer Healthcare
Pfizer

Amy Schulman is an innovative, results-focused leader and a champion for diversity and women’s professional advancement. Since 2008 she has led the Pfizer Legal Division, which handles some of the most complex, challenging legal matters within a highly regulated industry. Additionally, Ms Schulman leads Pfizer's Consumer Healthcare (PCH) - a global $4 billion business that operates in more than 90 countries. She also serves as Executive Sponsor of Pfizer’s Global Women’s Council.

In 2012 Ms Schulman was instrumental in the sale of Pfizer Nutrition to Nestle for $11.85 billion after assuming responsibility for the business in 2010. While President of the $2.1 billion, global business and leading provider of infant formulas and other nutritional products, Ms Schulman led the business to increased profitability and above-market performance.

Ms Schulman is a recipient of the 2012 Margaret Brent Women Lawyers of Achievement Award. She was named one of 10 “leading lights” in The Financial Times’ 2011 U.S. Innovative Lawyers report and was listed on Forbes’ 2009 list of “The World’s Most Powerful Women.” A graduate of Wesleyan University, Ms Schulman earned her J.D. from Yale Law School. She serves on the Board of Directors for Wesleyan University.

 
Jonathan Sheffield OBE
Chief Executive Officer
National Institute for Health Research Clinical Research Network

Dr Jonathan Sheffield is Chief Executive of the National Institute for Health Research Clinical Research Network.  This organisation is funded by the Department of Health to support the practical delivery of both academic and commercial clinical research in the NHS, and was responsible for recruiting more than half a million patients into clinical studies last year.

Dr Sheffield trained as a doctor at Dundee University, before following a career as a histopathologist at Yeovil District Hospital, where he was instrumental in developing its research capabilities.  In 2003 he became Medical Director for the Trust, before moving on to University Hospitals Bristol - again as Medical Director.

In 2009, he was awarded an OBE for services to the NHS.  In 2011 he was elected an Honorary Fellow of the Royal College of Physicians’ Faculty of Pharmaceutical Medicine – its highest honour - for his contribution in the area of clinical research delivery.

A passionate advocate for clinical research, Dr Sheffield’s ambition is for participation in a suitable research study to be a standard treatment option, open to all NHS patients.
 
Michael Warmuth
Executive Vice President, Established Pharmaceuticals
Abbott

Michael Warmuth is Executive Vice President, Established Pharmaceuticals, focusing on expanding the global market for Abbott’s portfolio of branded generic pharmaceuticals. He was appointed to his current role in November 2012.

Most recently, Mr Warmuth served as Senior Vice President, Established Pharmaceuticals, which previously operated as part of Abbott’s global pharmaceutical business. Mr Warmuth joined Abbott in 1986 as part of Abbott's manufacturing professional development program. He served in a variety of management roles including Senior Vice President, Diagnostics, heading Abbott’s global core laboratory Diagnostics business; Vice President and General Manager, Hematology, in Abbott's Diagnostics business; Vice President, Global Engineering Services; Divisional Vice President of Pharmaceutical Operations; and Divisional Vice President of Corporate Quality Operations.

He earned a Bachelor's degree in Business Administration from the University of Wisconsin-Whitewater and a Master's degree in Business Administration from Northwestern University.